Chronic topical administration of WIN-55-212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects

Hosseini, Alireza; Lattanzio, Frank A.; Williams, Patricia B.; Tibbs, DavidJ.; Samudre, S. S.; Allen, Robert C.

doi:10.1016/j.exer.2005.09.017

Cited by 21 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, a recent study demonstrated that 4 weeks of topical treatment with Tocrisolve TM did not cause ocular inflammation, conjunctival chemosis/swelling, conjunctival discharge, aqueous flare or fibrin, diminished corneal light reflex, iris or corneal opacity, or corneal vascularization/staining. 30 This is consistent with the findings of the current study.…”

Section: Discussionsupporting

confidence: 95%

Comparison of Topical and Intravenous Administration of WIN 55-212-2 in Normotensive Rabbits

Samudre

Schneider

Oltmanns

et al. 2008

Current Eye Research

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 95%

Comparison of Topical and Intravenous Administration of WIN 55-212-2 in Normotensive Rabbits

Samudre

Schneider

Oltmanns

et al. 2008

Current Eye Research

View full text Add to dashboard Cite

show abstract

“…Although there is information about CB1R, vanilloid receptor (TRPV), and fatty acid amide hydrolase (FAAH) roles in glaucoma and after retinal ischemia (Hosseini et al,2006; Nucci et al,2007), little is known about the role of CB2Rs in such models and in other models of retinal regeneration.…”

Section: Discussionmentioning

confidence: 99%

Distribution of CB2 cannabinoid receptor in adult rat retina

López

Tagliaferro

Onaivi

et al. 2010

Synapse

View full text Add to dashboard Cite

Cannabinoid effects are mediated through two receptors, CB1 and CB2. In the retina CB1 has been reported in bipolar cells, gabaergic amacrine cells, horizontal cells, and inner plexiform layer. CB2 receptor mRNA localization was shown in photoreceptors, inner nuclear layer, and ganglion cell layer by using RT-PCR. The aim of this work was to localize CB2 receptor in the rat retina by using immunocytochemistry. Our results showed that CB2 receptor was localized in retinal pigmentary epithelium, inner photoreceptor segments, horizontal and amacrine cells, cells localized in ganglion cell layer, and in fibers of inner plexiform layer. These results are in agreement with studies using RT-PCR and provide some additional information about the distribution of CB2 receptor. Further studies are needed to clarify the role of this cannabinoid receptor in the retina.

show abstract

“…Most studies have reported loss of effect of IOP lowering properties within a matter of hours [ 49 , 50 , 57 ]. However, a study by Hosseini and colleagues [ 84 ] found that chronic topical application of 0.5% WIN 55,212-2 was effective at reducing IOP for four weeks. This suggests that certain dosing parameters may allow for better long-term efficacy.…”

Section: Use Of Cannabinoids For Long-term Treatment Of Glaucomamentioning

confidence: 99%

The Endocannabinoid System as a Therapeutic Target in Glaucoma

2016

View full text Add to dashboard Cite

Glaucoma is an irreversible blinding eye disease which produces progressive retinal ganglion cell (RGC) loss. Intraocular pressure (IOP) is currently the only modifiable risk factor, and lowering IOP results in reduced risk of progression of the disorder. The endocannabinoid system (ECS) has attracted considerable attention as a potential target for the treatment of glaucoma, largely due to the observed IOP lowering effects seen after administration of exogenous cannabinoids. However, recent evidence has suggested that modulation of the ECS may also be neuroprotective. This paper will review the use of cannabinoids in glaucoma, presenting pertinent information regarding the pathophysiology of glaucoma and how alterations in cannabinoid signalling may contribute to glaucoma pathology. Additionally, the mechanisms and potential for the use of cannabinoids and other novel agents that target the endocannabinoid system in the treatment of glaucoma will be discussed.

show abstract

Chronic topical administration of WIN-55-212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects

Cited by 21 publications

References 25 publications

Comparison of Topical and Intravenous Administration of WIN 55-212-2 in Normotensive Rabbits

Comparison of Topical and Intravenous Administration of WIN 55-212-2 in Normotensive Rabbits

Distribution of CB2 cannabinoid receptor in adult rat retina

The Endocannabinoid System as a Therapeutic Target in Glaucoma

Contact Info

Product

Resources

About